Different ventricular remodelling and autonomic modulation after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic dilated cardiomyopathy

J Cardiovasc Med (Hagerstown). 2007 Oct;8(10):840-5. doi: 10.2459/JCM.0b013e328011708b.

Abstract

Objective: In this retrospective analysis, we investigated the influence of aetiology on autonomic modulation and reverse ventricular remodelling induced by beta-blockade in heart failure.

Methods: Twenty-three heart failure patients without comorbidities (mean age 61 +/- 4 years, New York Heart Association class 3.1 +/- 0.1, treated with angiotensin-converting enzyme inhibitors and diuretics) were divided into three groups according to aetiology: hypertensive (group 1, n = 7), ischaemic (group 2, n = 6), and idiopathic (group 3, n = 10). Before and after 6 months of carvedilol (53 +/- 10 mg/day), patients underwent cardiopulmonary test, echocardiography and autonomic evaluation with spectral analysis of RR variability (10 min of rest plus 10 min of standing: the low frequency/high frequency ratio between low and high frequency components of each spectrum was the index of sympathovagal balance).

Results: Carvedilol improved New York Heart Association class and exercise performance. In group 1, ejection fraction and left ventricular end-diastolic volume normalised, and interventricular septum thickness increased. No remodelling occurred in group 2. In group 3, interventricular septum thickness was unchanged, ejection fraction and left ventricular end-diastolic volume improved. Also autonomic modulation differed. At baseline, adrenergic activation was observed either at rest or during standing. After carvedilol treatment, group 1 did not show any change in the low frequency/high frequency ratio in both conditions, whereas groups 2 and 3 showed reduced adrenergic activation at rest and normal response to standing.

Conclusions: Despite favourable ventricular remodelling, the poor autonomic modulation observed with beta-blockade indicates a persistent central adrenergic activation in hypertensive heart failure patients.

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage*
  • Autonomic Nervous System / physiopathology
  • Carbazoles / administration & dosage*
  • Cardiomyopathy, Dilated / drug therapy*
  • Cardiomyopathy, Dilated / etiology
  • Cardiomyopathy, Dilated / physiopathology*
  • Carvedilol
  • Humans
  • Hypertension / complications*
  • Middle Aged
  • Propanolamines / administration & dosage*
  • Stroke Volume / physiology
  • Ventricular Remodeling / physiology*

Substances

  • Adrenergic beta-Antagonists
  • Carbazoles
  • Propanolamines
  • Carvedilol